Physician profile
Harsh Gupta
NPI 1235413196
$6,848.60
in general payments reported to CMS, 2019-2025
27 companies · $623 in 2025
The $623 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,718 · 2020: $731 · 2021: $61.31 · 2022: $1,155 · 2023: $169 · 2024: $2,391 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,210 · Travel and Lodging: $973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,210.30 |
| Travel and Lodging | $973.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,450.09 | 2019-2025 | Vercise |
| Medtronic, INC. | $1,046.32 | 2022-2024 | Percept PC Brainsense |
| Abbott Laboratories | $782.40 | 2019-2024 | Infinity |
| Mdd US Operations, LLC | $755.85 | 2019-2020 | |
| Grifols Shared Services North America, INC. | $294.71 | 2025 | Gamunex-C |
| Alexion Pharmaceuticals, INC. | $235.22 | 2024 | Soliris, Ultomiris |
| Amgen INC. | $181.13 | 2024-2025 | Uplizna |
| Acorda Therapeutics, INC | $146.14 | 2019 | |
| Ucb, INC. | $135.00 | 2024 | Rystiggo |
| Merz North America, INC. | $125.98 | 2019 | |
| Grifols USA, LLC | $121.36 | 2024 | Gamunex-C |
| Argenx US, INC. | $98.85 | 2024 | Vyvgart Hytrulo |
| Ipsen Biopharmaceuticals, INC | $90.07 | 2025 | Dysport |
| Abbvie INC. | $74.58 | 2023-2024 | |
| Allergan, INC. | $54.82 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $42.04 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $37.90 | 2021 | |
| Horizon Therapeutics Plc | $29.68 | 2023 | Uplizna |
| Natus Medical Incorporated | $25.18 | 2020 | |
| Lundbeck LLC | $21.06 | 2024 | Vyepti |
| Shire North American Group INC | $20.01 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.93 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $17.97 | 2025 | Benlysta |
| Amicus Therapeutics, INC. | $11.86 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.55 | 2021 | |
| Amneal Pharmaceuticals LLC | $11.25 | 2020 | |
| Travere Therapeutics, INC. | $8.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harsh Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.